Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

作者：Ursula A. Matulonis, Ronnie Shapira‐Frommer, Alessandro D. Santin, Alla Lisyanskaya, Sandro Pignata, Ignace Vergote, Francesco Raspagliesi, Gabe S. Sonke, Michael J. Birrer, Diane Provencher, Jalid Sehouli, Nicoletta Colombo, Antonio González-Martı́n, Ana Oaknin, Petronella B. Ottevanger, Vilius Rudaitis, Kianoosh Katchar, Huita Wu, Stephen J. O’Keefe, Jane Ruman, Jonathan A. Ledermann · 发表于：Annals of Oncology · 年份：2019 · DOI：10.1093/annonc/mdz135 · 被引用次数：854 · 研究领域：Cancer Immunotherapy and Biomarkers、Ovarian cancer diagnosis and treatment、PARP inhibition in cancer therapy